FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3024421700> ?p ?o ?g. }

• W3024421700 endingPage "197" @default.
• W3024421700 startingPage "193" @default.
• W3024421700 abstract "To analyze the effect of amide Valley on the immune function of ovarian cancer mice treated with paclitaxel. Fifty SPF female BALB/c mice were selected as experimental subjects, and the mice were divided into five groups, namely normal control group, tumor control group, paclitaxel group, glutamine group and combined intervention group, with 10 mice in each group. Except for the normal control group, the other 40 mice were all subjected to ovarian cancer modeling. After modeling, the tumor control group mice were injected with saline at a dose of 25 mg/kg; the mice in the paclitaxel group were given a dose of 25 mg/kg. Intraperitoneal injection of paclitaxel; mice in the glutamine group were intraperitoneally injected with glutamine at a dose of 25 mg/kg; mice in the joint intervention group were intraperitoneally injected with glutamine and paclitaxel at a dose of 25 mg/kg once daily. The normal control mice did not receive any treatment. Observe and compare the status of the five groups of mice and regularly measure the quality of the mice; after 2 weeks of treatment, the CD3+, CD4, CD4+, CD8, CD8+ of the T lymphocyte subsets of each group of mice were detected by flow cytometry calculate the ratio of CD4 / CD8. The tumor formation rate of mouse ovarian cancer was 95% (38/40). The hair color, diet, excretion and activity of mice in the normal control group were normal, while the hair of the remaining four groups of ovarian cancer mice was sparse and dull compared with those in the normal control group, and the diet was decreased and the action was retarded. By measuring the body mass of mice at a regular time, we found that before treatment, the body mass of the other four groups of ovarian cancer mice increased significantly (P< 0.05) because of the tumor body compared with the normal control group mice; after treatment, compared with the other ovarian cancer mice group, the body mass of the combined intervention group mice decreased significantly, the difference was statistically significant (P< 0.05), suggesting that the tumor body was reduced. Compare with normal control mice, CD3+, CD4, and CD4 / CD8 of other ovarian cancer mice groups were significantly decreased, and CD8+ was significantly increased, the differences were statistically significant (P< 0.05); There was no significant difference in the levels of CD3+, CD4+, CD4 / CD8, and CD8+ between the tumor control group and the paclitaxel group (P> 0.05). Paclitaxel does not improve the immunity of patients during the treatment of ovarian cancer. Glutamine is effective immunomodulation. By regulating paclitaxel-treated ovarian cancer mice, it can simultaneously treat ovarian cancer, significantly improve the immune function of ovarian cancer mice, thereby improving the anti-tumor ability, and provide the possibility of significantly improving the body's immunity of ovarian cancer patients. Clinical research and long-term prognosis still need to be confirmed by further studies." @default.
• W3024421700 created "2020-05-21" @default.
• W3024421700 creator A5012278873 @default.
• W3024421700 creator A5018892762 @default.
• W3024421700 creator A5090797299 @default.
• W3024421700 date "2020-05-16" @default.
• W3024421700 modified "2023-10-12" @default.
• W3024421700 title "Effect of glutamine on the immune function of paclitaxel intervention in ovarian cancer mice" @default.
• W3024421700 cites W1742516846 @default.
• W3024421700 cites W1991429659 @default.
• W3024421700 cites W2019271546 @default.
• W3024421700 cites W2040307459 @default.
• W3024421700 cites W2060592426 @default.
• W3024421700 cites W2086920105 @default.
• W3024421700 cites W2090880672 @default.
• W3024421700 cites W2117332972 @default.
• W3024421700 cites W2162016905 @default.
• W3024421700 cites W2165535625 @default.
• W3024421700 cites W2288638264 @default.
• W3024421700 cites W2485902354 @default.
• W3024421700 cites W2565791443 @default.
• W3024421700 cites W2581431829 @default.
• W3024421700 cites W2746379258 @default.
• W3024421700 cites W2753475483 @default.
• W3024421700 cites W2768405172 @default.
• W3024421700 cites W2779563463 @default.
• W3024421700 cites W2790532714 @default.
• W3024421700 cites W2799606148 @default.
• W3024421700 cites W2806638746 @default.
• W3024421700 cites W2921884745 @default.
• W3024421700 cites W2965172271 @default.
• W3024421700 cites W3007736933 @default.
• W3024421700 cites W3030269144 @default.
• W3024421700 cites W3030722814 @default.
• W3024421700 doi "https://doi.org/10.14715/cmb/2020.66.2.30" @default.
• W3024421700 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32415947" @default.
• W3024421700 hasPublicationYear "2020" @default.
• W3024421700 type Work @default.
• W3024421700 sameAs 3024421700 @default.
• W3024421700 citedByCount "2" @default.
• W3024421700 countsByYear W30244217002022 @default.
• W3024421700 countsByYear W30244217002023 @default.
• W3024421700 crossrefType "journal-article" @default.
• W3024421700 hasAuthorship W3024421700A5012278873 @default.
• W3024421700 hasAuthorship W3024421700A5018892762 @default.
• W3024421700 hasAuthorship W3024421700A5090797299 @default.
• W3024421700 hasBestOaLocation W30244217001 @default.
• W3024421700 hasConcept C121608353 @default.
• W3024421700 hasConcept C126322002 @default.
• W3024421700 hasConcept C134018914 @default.
• W3024421700 hasConcept C167672396 @default.
• W3024421700 hasConcept C185592680 @default.
• W3024421700 hasConcept C203014093 @default.
• W3024421700 hasConcept C2777292972 @default.
• W3024421700 hasConcept C2779349466 @default.
• W3024421700 hasConcept C2780159080 @default.
• W3024421700 hasConcept C2780427987 @default.
• W3024421700 hasConcept C515207424 @default.
• W3024421700 hasConcept C55493867 @default.
• W3024421700 hasConcept C71924100 @default.
• W3024421700 hasConcept C8891405 @default.
• W3024421700 hasConceptScore W3024421700C121608353 @default.
• W3024421700 hasConceptScore W3024421700C126322002 @default.
• W3024421700 hasConceptScore W3024421700C134018914 @default.
• W3024421700 hasConceptScore W3024421700C167672396 @default.
• W3024421700 hasConceptScore W3024421700C185592680 @default.
• W3024421700 hasConceptScore W3024421700C203014093 @default.
• W3024421700 hasConceptScore W3024421700C2777292972 @default.
• W3024421700 hasConceptScore W3024421700C2779349466 @default.
• W3024421700 hasConceptScore W3024421700C2780159080 @default.
• W3024421700 hasConceptScore W3024421700C2780427987 @default.
• W3024421700 hasConceptScore W3024421700C515207424 @default.
• W3024421700 hasConceptScore W3024421700C55493867 @default.
• W3024421700 hasConceptScore W3024421700C71924100 @default.
• W3024421700 hasConceptScore W3024421700C8891405 @default.
• W3024421700 hasIssue "2" @default.
• W3024421700 hasLocation W30244217001 @default.
• W3024421700 hasOpenAccess W3024421700 @default.
• W3024421700 hasPrimaryLocation W30244217001 @default.
• W3024421700 hasRelatedWork W2008264923 @default.
• W3024421700 hasRelatedWork W2052455532 @default.
• W3024421700 hasRelatedWork W2061182616 @default.
• W3024421700 hasRelatedWork W2118505283 @default.
• W3024421700 hasRelatedWork W2145427567 @default.
• W3024421700 hasRelatedWork W2153965615 @default.
• W3024421700 hasRelatedWork W2287759402 @default.
• W3024421700 hasRelatedWork W2364659991 @default.
• W3024421700 hasRelatedWork W3024421700 @default.
• W3024421700 hasRelatedWork W311287571 @default.
• W3024421700 hasVolume "66" @default.
• W3024421700 isParatext "false" @default.
• W3024421700 isRetracted "false" @default.
• W3024421700 magId "3024421700" @default.
• W3024421700 workType "article" @default.